Gene-expression signatures: Biomarkers toward diagnosing multiple sclerosis

Genes and Immunity

Volumn 13, Issue 2, 2012, Pages 146-154

  Tossberg, J T ^a   Crooke, P S ^b   Henderson, M A ^c   Sriram, S ^c   Mrelashvili, D ^d   Chitnis, S ^e   Polman, C ^f   Vosslamber, S ^f   Verweij, C L ^f   Olsen, N J ^g   Aune, T M ^c  

^a ArthroChip LLC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

diagnosis; genomics; multiple sclerosis

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; BIOLOGICAL MARKER; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DECAY ACCELERATING FACTOR; INTERLEUKIN 11 RECEPTOR ALPHA; K RAS PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN ACTB; PROTEIN ACTR1A; PROTEIN ADAMTSL4; PROTEIN ANAPC1; PROTEIN ASL; PROTEIN B2M; PROTEIN CSF3R; PROTEIN CTSS; PROTEIN EPHX2; PROTEIN EXT2; PROTEIN FOS; PROTEIN FOSL1; PROTEIN GNB5; PROTEIN NRAS; PROTEIN P53; PROTEIN RANGAP1; PROTEIN SPIB; PROTEIN TXK; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; VALIDATION STUDY;

BIOLOGICAL MARKERS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE SCLEROSIS;

EID: 84857790320     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.66     Document Type: Article

References (30)

1. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007; 6: 664-665.
2. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005. revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
3. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
4. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2009; 219: 1-7.
5. LInk H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006; 180: 17-28.
6. Consortium TWTCC. Genome-wide association study of 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-678.
7. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-412.
8. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009; 13: e7440.
9. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009; 13: 225-244.
10. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008; 105: 18889-18894.
11. Kostka D, Spang R. Microarray based diagnosis profits from better documentation of gene expression signatures. PLoS Comput Biol 2008; 4: e22.
12. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362.
13. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463-2472.
14. Hofman P. DNA Microarrays. Nephron Physiol 2005; 99: 85-89.
15. Gregersen PK, Brehrens TW. Fine mapping the phenotype in autoimmune disease: the promise and pitfalls of DNA microarray technologies. Genes Immun 2003; 4: 175-176.
16. Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003; 12: 2191-2199.
17. Brynedal B, Khademi M, Wallström E, Hillert J, Olsson T, Duvefelt K. Gene expression proling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2010; 37: 613-621.
18. Harris VK, Sadiq SA. Disease biomarkers: potential for use in therapeutic decision making. Mol Diagn Ther 2009; 13: 225-244.
19. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
20. Liu Z, Maas K, Aune TM. Identification of gene expression signatures in autoimmune disease without the influence of familial resemblance. Hum Mol Genet 2006; 15: 501-509.
21. Maas K, Chen H, Shyr Y, Olsen NJ, Aune T. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Hum Mol Genet 2005; 14: 1305-1314.
22. Fossey SC, Vnencak-Jones CL, Olsen NJ, Sriram S, Garrison G, Deng X et al. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 2007; 9: 197-204.
23. Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 583-588.
24. Shao L, Fujii H, Colmegna I, Oishi H, Goronzy JJ,Weyand CM. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 2009; 206: 1435-1449.
25. Deng X, Ljunggren-Rose A, Maas K, Sriram S. Defective ATMp53-mediated apoptotic pathway in multiple sclerosis. Ann Neurol 2005; 58: 577-584.
26. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiationinduced apoptosis. Arthritis Rheum 2005; 52: 1047-1057.
27. Butowski N. Immunostimulants for malignant gliomas. Neurosurg Clin N Am 2010; 21: 53-65.
28. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev 2009; 228: 93-114.
29. Buchner DA, Meisler MH. TSRC1, a widely expressed gene containing seven thrombospondin type I repeats. Gene 2003; 307: 23-30.
30. Abdi H. The Bonferonni and Sidak Corrections for Multiple Comparisons. Sage: Thousand Oaks, CA, 2007.